Zoledronate suppresses VEGF‑induced capillary tube formation and inhibits expression of interferon‑induced transmembrane protein‑1 in human umbilical vein endothelial cells

Kim,Beom Su; Yang,Sun‑Sik; Kim,Cheol‑Sang; Lee,Jun

doi:10.3892/ijmm.2018.3497

Zoledronate suppresses VEGF‑induced capillary tube formation and inhibits expression of interferon‑induced transmembrane protein‑1 in human umbilical vein endothelial cells

Authors:
- Beom Su Kim
- Sun‑Sik Yang
- Cheol‑Sang Kim
- Jun Lee
View Affiliations

Affiliations: Carbon Nano Convergence Technology Center for Next Generation Engineers, Chonbuk National University, Jeonju, North Jeolla 54896, Republic of Korea, Bonecell Biotech Inc., Daejeon, South Chungcheong 302‑830, Republic of Korea
Published online on: February 16, 2018 https://doi.org/10.3892/ijmm.2018.3497
Pages: 2879-2884

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Interferon‑induced transmembrane protein 1 (IFITM1) is a member of the interferon‑induced transmembrane protein family and has recently been identified as a novel protein participant in angiogenesis. Zoledronate (ZON), a nitrogen‑containing bisphosphonate, is widely used in the treatment of osteoporosis and to prevent bone metastases of certain cancer types. However, the association between ZON and IFITM1 has remained elusive. The present study investigated the effect of ZON on the expression of IFITM1 during vascular endothelial growth factor (VEGF)‑induced capillary tube formation in human umbilical vein endothelial cells. It was observed that cell proliferation and VEGF‑induced tube formation were significantly inhibited by treatment with 10 µM ZON. The expression of IFITM1 increased during VEGF‑induced tube formation. However, the VEGF‑induced increase in IFITM1 expression exhibited a dose‑ and time‑dependent decrease with ZON treatment at the mRNA and protein level. Furthermore, matrix metalloproteinase‑9 activation was markedly decreased by ZON treatment. These results suggest that induction of IFITM1 expression may be involved in the anti‑angiogenic activity of ZON.

View Figures

View References

1	Marx RE: Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg. 61:1115–1117. 2003. View Article : Google Scholar : PubMed/NCBI
2	Marx RE, Sawatari Y, Fortin M and Broumand V: Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 63:1567–1575. 2005. View Article : Google Scholar : PubMed/NCBI
3	Pires FR, Miranda A, Cardoso ES, Cardoso AS, Fregnani ER, Pereira CM, Correa ME, Almeida JP, Alves Fde A, Lopes MA and de Almeida OP: Oral avascular bone necrosis associated with chemotherapy and biphosphonate therapy. Oral Dis. 11:365–369. 2005. View Article : Google Scholar : PubMed/NCBI
4	Sharma D, Ivanovski S, Slevin M, Hamlet S, Pop TS, Brinzaniuc K, Petcu EB and Miroiu RI: Bisphosphonate-related osteonecrosis of jaw (BRONJ): Diagnostic criteria and possible pathogenic mechanisms of an unexpected anti-angiogenic side effect. Vasc Cell. 5:12013. View Article : Google Scholar : PubMed/NCBI
5	Petcu EB, Ivanovski S, Wright RG, Slevin M, Miroiu RI and Brinzaniuc K: Bisphosphonate-related osteonecrosis of jaw (BRONJ): An anti-angiogenic side-effect? Diagn Pathol. 7:782012. View Article : Google Scholar : PubMed/NCBI
6	Otrock ZK, Mahfouz RAR, Makarem JA and Shamseddine AI: Understanding the biology of angiogenesis: Review of the most important molecular mechanisms. Blood Cells Mol Dis. 39:212–220. 2007. View Article : Google Scholar : PubMed/NCBI
7	Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM, Castronovo V and Green JR: Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther. 302:1055–1061. 2002. View Article : Google Scholar : PubMed/NCBI
8	Yamada J, Tsuno NH, Kitayama J, Tsuchiya T, Yoneyama S, Asakage M, Okaji Y, Shuno Y, Nishikawa T, Tanaka J, et al: Anti-angiogenic property of zoledronic acid by inhibition of endothelial progenitor cell differentiation. J Surg Res. 151:115–120. 2009. View Article : Google Scholar
9	Brass AL, Huang IC, Benita Y, John SP, Krishnan MN, Feeley EM, Ryan BJ, Weyer JL, van der Weyden L, Fikrig E, et al: The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus. Cell. 139:1243–1254. 2009. View Article : Google Scholar
10	Hatano H, Kudo Y, Ogawa I, Tsunematsu T, Kikuchi A, Abiko Y and Takata T: IFN-induced transmembrane protein 1 promotes invasion at early stage of head and neck cancer progression. Clin Cancer Res. 14:6097–6105. 2008. View Article : Google Scholar : PubMed/NCBI
11	Yu F, Ng SS, Chow BK, Sze J, Lu G, Poon WS, Kung HF and Lin MC: Knockdown of interferon-induced transmembrane protein 1 (IFITM1) inhibits proliferation, migration, and invasion of glioma cells. J Neurooncol. 103:187–195. 2011. View Article : Google Scholar
12	Pan Z, Chen S, Pan X, Wang Z, Han H, Zheng W, Wang X, Li F, Qu S and Shao R: Differential gene expression identified in uigur women cervical squamous cell carcinoma by suppression subtractive hybridization. Neoplasma. 57:123–128. 2010. View Article : Google Scholar : PubMed/NCBI
13	Popson SA, Ziegler ME, Chen X, Holderfield MT, Shaaban CI, Fong AH, Welch-Reardon KM, Papkoff J and Hughes CC: Interferon-induced transmembrane protein 1 regulates endothelial lumen formation during angiogenesis. Arterioscler Thromb Vasc Biol. 34:1011–1019. 2014. View Article : Google Scholar : PubMed/NCBI
14	Schmittgen TD and Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
15	Vescovi P, Merigo E, Meleti M, Manfredi M, Guidotti R and Nammour S: Bisphosphonates-related osteonecrosis of the jaws: A concise review of the literature and a report of a single-centre experience with 151 patients. J Oral Pathol Med. 41:214–221. 2012. View Article : Google Scholar
16	Bagan JV, Murillo J, Jimenez Y, Poveda R, Milian MA, Sanchis JM, Silvestre FJ and Scully C: Avascular jaw osteonecrosis in association with cancer chemotherapy: Series of 10 cases. J Oral Pathol Med. 34:120–123. 2005. View Article : Google Scholar : PubMed/NCBI
17	Misso G, Porru M, Stoppacciaro A, Castellano M, De Cicco F, Leonetti C, Santini D and Caraglia M: Evaluation of the in vitro and in vivo antiangiogenic effects of denosumab and zoledronic acid. Cancer Biol Ther. 13:1491–1500. 2012. View Article : Google Scholar : PubMed/NCBI
18	Ponce ML: Tube formation: An in vitro matrigel angiogenesis assay. Methods Mol Biol. 467:183–188. 2009. View Article : Google Scholar : PubMed/NCBI
19	Michailidou M, Brown HK, Lefley DV, Evans A, Cross SS, Coleman RE, Brown NJ and Holen I: Microvascular endothelial cell responses in vitro and in vivo: Modulation by zoledronic acid and paclitaxel? J Vasc Res. 47:481–493. 2010. View Article : Google Scholar : PubMed/NCBI
20	Fournier P, Boissier S, Filleur S, Guglielmi J, Cabon F, Colombel M and Clezardin P: Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res. 62:6538–6544. 2002.PubMed/NCBI
21	Coxon JP, Oades GM, Kirby RS and Colston KW: Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation. BJU Int. 94:164–170. 2004. View Article : Google Scholar : PubMed/NCBI
22	Tsai SH, Huang PH, Chang WC, Tsai HY, Lin CP, Leu HB, Wu TC, Chen JW and Lin SJ: Zoledronate inhibits ischemia-induced neovascularization by impairing the mobilization and function of endothelial progenitor cells. PLoS One. 7:e410652012. View Article : Google Scholar : PubMed/NCBI
23	Di Salvatore M, Orlandi A, Bagala C, Quirino M, Cassano A, Astone A and Barone C: Anti-tumour and anti-angiogenetic effects of zoledronic acid on human non-small-cell lung cancer cell line. Cell Prolif. 44:139–146. 2011. View Article : Google Scholar : PubMed/NCBI
24	Li S and De Souza P: Ras Isoprenylation and pAkt Inhibition by zoledronic acid and fluvastatin enhances paclitaxel activity in T24 bladder cancer cells. Cancers (Basel). 3:662–674. 2011. View Article : Google Scholar
25	Jaffe EA, Armellino D, Lam G, Cordon-Cardo C, Murray HW and Evans RL: IFN-gamma and IFN-alpha induce the expression and synthesis of Leu 13 antigen by cultured human endothelial cells. J Immunol. 143:3961–3966. 1989.PubMed/NCBI
26	Yu F, Ng SSM, Chow BKC, Sze J, Lu G, Poon WS, Kung HF and Lin MCM: Knockdown of interferon-induced transmembrane protein 1 (IFITM1) inhibits proliferation, migration, and invasion of glioma cells. J Neurooncol. 103:187–195. 2011. View Article : Google Scholar
27	Tanaka SS, Yamaguchi YL, Tsoi B, Lickert H and Tam PP: IFITM/Mil/fragilis family proteins IFITM1 and IFITM3 play distinct roles in mouse primordial germ cell homing and repulsion. Dev Cell. 9:745–756. 2005. View Article : Google Scholar : PubMed/NCBI
28	Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z and Hanahan D: Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nature Cell Biol. 2:737–744. 2000. View Article : Google Scholar : PubMed/NCBI